

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 7/29/1984
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Crohn Disease Prognostic Panel

ARUP test code 2001613

Saccharomyces cerevisiae Ab (gASCA), IgG	5 units (Ref Interval: 0-50) INTERPRETIVE INFORMATION: Anti-Saccharomyces cerevisiae Antibody (gASCA), IgG 0-44 Units: Negative 45-50 Units: Equivocal 51 Units or greater: Positive
--	--

Laminaribioside Carbohydrate Ab ALCA IgG	6 units (Ref Interval: 0-60) INTERPRETIVE INFORMATION: Anti-Laminaribioside Carbohydrate Antibody (ALCA), IgG 0-54 Units: Negative 55-60 Units: Equivocal 61 Units or greater: Positive
--	---

Mannobioside Carbohydrate Ab (AMCA), IgG	8 units (Ref Interval: 0-100) INTERPRETIVE INFORMATION: Anti-Mannobioside Carbohydrate Antibody (AMCA), IgG 0-89 Units: Negative 90-100 Units: Equivocal 101 Units or greater: Positive
--	---

Chitobioside Carbohydrate Ab (ACCA), IgA	21 units (Ref Interval: 0-90) INTERPRETIVE INFORMATION: Anti-Chitobioside Carbohydrate Antibody (ACCA), IgA 0-79 Units: Negative 80-90 Units: Equivocal 91 Units or greater: Positive
--	---

Crohn Disease Prognostic Pan Interp.	See Note
--------------------------------------	----------

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: Crohn Disease Prognostic Panel

Anti-glycan serologic markers may serve as an aid in the diagnosis of Crohn disease (CD) and an indicator of disease prognosis. Anti-saccharomyces cerevisiae antibody (gASCA) has the highest diagnostic value and anti-chitobioside carbohydrate antibody (ACCA) has the highest association with more-aggressive disease. Both ACCA and gASCA are associated equally with the need for surgery. When found in combination, these markers have the best diagnostic potential. A combination of two or more of the four anti-glycan markers have a significant association with complications and the need for surgery than any single marker alone. A negative result does not rule out CD.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Saccharomyces cerevisiae Ab (gASCA), IgG	21-076-137422	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Laminaribioside Carbohydrate Ab ALCA IgG	21-076-137422	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Mannobioside Carbohydrate Ab (AMCA), IgG	21-076-137422	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Chitobioside Carbohydrate Ab (ACCA), IgA	21-076-137422	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Crohn Disease Prognostic Pan Interp.	21-076-137422	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: